Metabolon to Fuel Population Health Enriched Metabolomics Studies at FinnGen
FinnGen Selects Metabolon’s Global Metabolomics Platform to Complement Genomic and Clinical Datasets to Gain New Insights and Improve Human Health
MUNICH and MORRISVILLE, North Carolina, January 25, 2022 /PRNewswire/ — Metabolon Inc.through its wholly owned subsidiary, Metabolon GmbHannounces a multi-year collaboration with the FinnGen study in Finland provide metabolomics data for population health studies to improve understanding of human health.
The Genomics Initiative will add in-depth metabolomics datasets to enrich current genomics and clinical datasets.
“We are very excited to enter into this collaboration with FinnGen which will create unique scientific and clinical insights from metabolomics data,” said Michel Rasche, President and Managing Director, International Affairs, Metabolon. “Our industry-leading metabolomics capabilities provide large cohort longitudinal studies with metabolomics expertise, datasets and interpretation.”
As a leading biobank research project based in Finland, FinnGen will integrate in-depth metabolomics datasets to better understand how genetic disease factors can impact biological function and influence disease progression. The world-class initiative has already identified more than 400 novel disease-associated variants enriched in the Finnish population. These results offer the possibility of further functional studies and new insights into disease mechanisms. FinnGen’s collaboration with Metabolon enables this by adding in-depth metabolomics data generated from a subset of study participants who carry some of these medically interesting genetic variants.
“One of FinnGen’s main interests is to understand the biological consequences of genetic disease-associated variants that are enriched in the Finnish population. Metabolomic analyzes have the potential to provide important insights to achieve this goal,” says Prof. Arno PalotieScientific Director FinnGen of the Finnish Institute of Molecular Medicine (FIMM), University of Helsinki.
Metabolon’s proprietary global metabolomics platform is optimized to detect and identify over 5,400 metabolites across 70 major biochemical pathways for a wide range of samples such as plasma, urine and tissues. Large-scale scientific research studies with this depth and breadth of global metabolomics data can derive new insights and insights from their current clinical and multi-omics datasets.
“FinnGen is an incredible genomics initiative that will now add extensive metabolomics datasets to enrich their current genomics and clinical datasets,” says Dr. Karl Quinn, Director of Population Health, International Affairs, Metabolon. “These combined datasets allow academic and pharmaceutical researchers to better understand the disease and conduct multi-omics analyzes to develop new biomarkers, diagnostic tools and new therapies.
FinnGen is coordinated by the University of Helsinki Finnish Institute of Molecular Medicine (FIMM). Since 2017, research collaborations around the world have published peer-reviewed articles on a wide variety of diseases, including neurology (epilepsy, Alzheimer’s, ischemic stroke), cardiology (atrial fibrillation, heart failure), endocrinology (type 2 diabetes, non-alcoholic fatty liver disease). disease), rheumatology (arthritis), respiratory (COVID-19) and various forms of cancer. Many of these studies used advanced bioinformatics techniques to analyze informal relationships between organ functions, genome-wide meta-analysis, and replicated results using FinnGen and other class biobanks. world for the benefit of people worldwide. See more on FinnGen peer-reviewed articles published to date.
Metabolon’s metabolomics platform offers greater potential for improving the stratification of patients by disease severity to highlight key biological differences between groups, providing novel precision medicine treatments or improved. These enriched datasets can support the search for new biomarkers, the diagnosis of diseases and the development of new therapies. Find out how Metabolon helps researchers achieve fully integrated multi-omics.
FinnGen and Metabolon look forward to collaborating to generate new datasets and insights that will enable important discoveries to improve human health.
The FinnGen study, launched in Finland in 2017, is a unique study that combines genome information with numerical healthcare data. The FinnGen study plans to analyze up to 500,000 samples collected by a nationwide network of Finnish biobanks. The project aims to improve human health through genetic research and ultimately to identify new therapeutic and diagnostic targets for the treatment of many diseases. It produces near-complete genome variant data from the 500,000 participants using genotyping and GWAS imputation and will use the extensive longitudinal National Health Registry data available on all Finns. FinnGen is an exceptionally broad academic-pharma partnership (see website below for full list of partners), with considerable public financial support from Business Finland (formerly Tekes). University of Helsinki is the organization responsible for the study. For more information, please visit http://www.finngen.fi/en and follow us on Twitter.
Metabolomics, the large-scale study of all small molecules in a biological system, is the only omics technology that provides a complete functional readout of the current state of a biological system. Metabolomics helps researchers see beyond the simple genetic variation of individuals, capturing the combined impact of genetic and external factors, such as the effect of drugs, diet, lifestyle and microbiome on human health. By measuring thousands of discrete chemical signals that form biological pathways in the body, metabolomics can reveal important biomarkers that can help understand a drug’s mechanism of action (MOA), pharmacodynamics, safety and individual response to treatment.
Metabolon, Inc., is the global leader in metabolomics, whose mission is to provide metabolomics data and insights that broaden and accelerate the impact of life science research in all its applications. In 20 years, more than 10,000 projects, more than 2,000 publications and ISO 9001:2015 and CLIA certifications, Metabolon has developed cutting-edge scientific technology and bioinformatics techniques. Our precision metabolomics™ The platform has enabled the development of the largest proprietary metabolomics reference library in the world. Our industry-leading data and translational science experts help our clients answer some of the toughest and most pressing questions in life sciences, accelerating research and development success. The company offers scalable and customizable metabolomics solutions, from discovery to clinical trials and product lifecycle management. For more information, please visit www.metabolon.com and follow us on LinkedIn and Twitter.
Show original content to download multimedia:https://www.prnewswire.com/news-releases/metabolon-to-power-metabolomic-enriched-population-health-studies-at-finngen-301467115.html
SOURCE Metabolon, Inc.